期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

多西他赛联合表柔比星治疗乳腺癌 被引量：2

下载PDF
导出
摘要 目的观察多西他赛与表柔比星联合辅助化疗治疗乳腺癌的临床疗效。方法从我院收治入院的乳腺癌拟行化疗患者中抽取60例,随机分为观察组与对照组,观察组使用多西他赛与表柔比星联合化疗,对照组使用表柔比星、氟尿嘧啶与环磷酰胺联合化疗,对比观察两组患者临床疗效。结果观察组患者治疗总有效率明显高于对照组,差异有统计学意义(P<0.05)。结论使多西他赛与表柔比星联合应用,在对乳腺癌患者的化疗中,具有更为显著的临床疗效,且无严重副作用,安全可靠,可以在临床上进一步推广应用。
作者 赵春玲
机构地区 辽宁省本溪市钢铁集团总医院
出处 《中国医药指南》 2013年第16期651-652,共2页 Guide of China Medicine
关键词 多西他赛 表柔比星 乳腺癌 联合化疗
分类号 R737.9 [医药卫生—肿瘤]
  • 相关文献

参考文献3

二级参考文献34

  • 1Garces CA, Cance WG. Neoadjuvant chemotherapy of breast cancer. Am Surg, 2004,70 : 565-569. 被引量：1
  • 2Charfare H, Limongelli S, Purushotham AD, et al. Neoadjuvant chemotherapy in breast cancer. Br J Surg,2005, 92:14-23. 被引量：1
  • 3Abrial SC, Penault-Llorca F, Delva R, et al. High prognostic significance of residual disease after neoadjuvant chemotherapy: a retrospective study in 710 patients with operable breast cancer. Breast Cancer Res Treat,2005, 94: 255-263. 被引量：1
  • 4Penault-Llorea F, Cayre A, Bouchet-Mishellany F, et al. Induction chemotherapy for breast carcinoma: predictive markers and relation with outcome. Int J Oncol,2003, 22: 1319-1325. 被引量：1
  • 5Petit T, Wilt M, Velten M, et al. Comparative value of tumor grade hormonal receptors, Ki 67, HER 2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy. Eur J Cancer, 2004,40 : 205 -211. 被引量：1
  • 6Gregory RK, Powles TJ, Salter J, et al. Prognostic relevance of CerhB2 expression following neoadjuvant chemotherapy in patients in a randomized trial of neoadjuvant versus adjuvant chemoendocrine therapy. Breast Cancer Res Treat, 2000,59 : 171 - 175. 被引量：1
  • 7Estevez LG, Guevas JM, Anton A, et al. Weekly docetaxel as neoadjuvant chemotherapy for stage II and III breast cancer: efficacy and correlation with biological markers in a phase II , muhicenter study. Clin Cancer Res,2003 ,9 :686-692. 被引量：1
  • 8Liedtke C, Mazouni C, Hess KR, et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol,2008 26 : 1275-1281. 被引量：1
  • 9Carey LA, Dees EC ,Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res ,2007,13:2329-2334. 被引量：1
  • 10Honkoop AH, Luykx-de Bakker SA, Hoekman K, et al. Prolonged neoadjuvant chemotherapy with GM-CSF in locally advanced breast cancer. Oncologist, 1999,4 : 106-111. 被引量：1

共引文献44

同被引文献32

  • 1Bouchbika Z, Haddad H, Benchakroun N, et al. Cancer incidence inMorocco : report from Casablanca registry 2005 - 2007 [ J ]. Pan Afr MedJ, 2013,16:31. 被引量：1
  • 2M Y,Ahmadi M R H, J K, et al. An 8 years retrospective study of breastcancer incidence in ilam province, Western iran[ J]. J Clin Diagn Res,2013,7(12):2923 - 2925. 被引量：1
  • 3Garg A,Li J, Clark E,et al. Exposure - response analysis of pertuzum-ab in HER2 - positive metastatic breast cancer : absence of effect onQTc prolongation and other ECG parameters [ J ]. Cancer ChemotherPharmacol, 2013 ,72(5 ) : 1133 - 1141. 被引量：1
  • 4Cedolini C,Bertozzi S, Seriau L, et al. Feasibility of concervativebreast surgery and intraoperative radiation therapy for early breast canc-er :A single - center,open,non - randomized,prospective pilot study[J]. Oncol Rep, 2014,31(4) : 1539 -1546. 被引量：1
  • 5Forget P, Bentin C, Machiels JP, et al. Intraoperative use of ketorolacor diclofenac is associated with improved disease - free survival and o-verall survival in conservative breast cancer surgery [ J ]. Br J Anaesth.2014,113 Suppl I:i82-i87. 被引量：1
  • 6Brenelli F,Rietjens M, De Lorenzi F, et al. Oncological safety of autol-ogous fat grafting after breast conservativetreatment : a prospective evalu-ation[J]. Breast J, 2014,20(2):159-165. 被引量：1
  • 7Jeon YW, Lim ST, Choi HJ, et al. Weight change and its impact onprognosis after adjuvant TAC ( docetaxel - doxorubicin - cyclophospha-mide )chemotherapy in Korean women with node — positive breast cancer[J]. Med Oncol, 2014,31(3) :849. 被引量：1
  • 8Donker M, Liti^re S, Werutsky G, et al. Breast - conserving treatmentwith or without radiotherapy in ductal carcinoma In Situ: 15 - year recur-rence rates and outcome after a recurrence,from the EORTC 10853 ran-domized phase III trial[ J]. J Clin Oncol, 2013 ,31 (32) :4054 - 4059. 被引量：1
  • 9Huang 0,Jiang M, Zhang X,et al. Grbl4 as an independent goodprognosis factor for breast cancer patients treated with neoadjuvant chem-otherapy [J] .Jpn J Clin Oncol, 2013 ,43( 11) :1064 - 1072. 被引量：1
  • 10von Minckwitz G, Blohmer JU, Costa SD, et al. Response - guidedneoadjuvant chemotherapy for breast cancer[ J]. J Clin Oncol,2013 ,31(29):3623 -3630. 被引量：1

引证文献2

二级引证文献25

中国医药指南
2013年 第16期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部